Skip to content
Biodatica
Start free

CSPC Megalith Biopharmaceutical Co.,Ltd.

Harbin, Heilongjiang

OncologymicrobiomePhase IIIListed · 1093.HK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase III trial registered: Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

2w agoTrial registeredJul 1, 2026Source filing (opens the source filing in a new tab)

Momentum

89no change

Momentum 89 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    May 23, 2025

    Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer · RECRUITING · sponsor: University of Colorado, Denver · Microbiome in Head and Neck Squamous Cell Carcinoma

    ClinicalTrials.gov · NCT05837221 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Mar 30, 2025

    EGFR-mutated Locally Advanced or Metastatic NSCLC · RECRUITING · sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

    ClinicalTrials.gov · NCT06927986 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Aug 15, 2024

    Advanced Solid Tumor · RECRUITING · sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

    ClinicalTrials.gov · NCT07110883 (opens the source filing in a new tab)

  4. Trial

    Study registered

    May 8, 2023

    Non Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Shanghai Chest Hospital · A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

    ClinicalTrials.gov · NCT06443684 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources